

## DAFTAR PUSTAKA

- Apri, S., & Desi, Y. M. A. (2016). Faktor-Faktor Determinat Terjadinya Kanker Ovarium Di Rumah Sakit Umum Daerah Abdoel Mpelok Provinsi Lampung 2015. *P- ISSN: 2086-3071, E-ISSN: 2443-0900, 7(2)*, 79–87.
- Bai, H., Sha, G., Xiao, M., Gao, H., Cao, D., Yang, J., Chen, J., Wang, Y., Zhang, Z., & Shen, K. (2016). The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: A two-academic-institute study. *Oncotarget, 7(13)*, 15566–15576.
- Bandera, E. V., Lee, V. S., Qin, B., Rodriguez-Rodriguez, L., Powell, C. B., & Kushi, L. H. (2017). Impact of body mass index on ovarian cancer survival varies by stage. *British Journal of Cancer, 117(2)*, 282–289.
- Berek, J., Crum, C., & Friedlander, M. (2015). FIGO Cancer Report 2015: Cancer of the ovary, fallopian tube, and peritoneum. *Elsevier, 131(October)*, S111–S122.
- Chen, G., Zhu, L., Yang, Y., Long, Y., Li, X., & Wang, Y. (2018). *Prognostic Role of Neutrophil to Lymphocyte Ratio in Ovarian Cancer : A Meta-Analysis. 17*, 1–8.
- Chen, S., Zhang, L., Yan, G., Cheng, S., Fathy, A. H., Yan, N., & Zhao, Y. (2017). Neutrophil-to-lymphocyte ratio is a potential prognostic biomarker in patients with ovarian cancer: A meta-analysis. *BioMed Research International, 2017*.
- Cho, H., Hur, H. W., Kim, S. W., Kim, S. H., Kim, J. H., Kim, Y. T., & Lee, K. (2009). Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. *Cancer Immunology, Immunotherapy, 58(1)*, 15–23.
- Cho, K. (2010). Ovarian Cancer. *Annu Rev Pathol, 4*, 287–313.

- Cristea, M., Han, E., Salmon, L., & Morgan, R. J. (2010). Review: Practical considerations in ovarian cancer chemotherapy. *Therapeutic Advances in Medical Oncology*, 2(3), 175–187.
- Dao, F., Schlappe, B., Tseng, J., Lester, J., Nick, A., Lutgendorf, S., McMeekin, S., Coleman, R., Moore, K., Karian, B., Sood, A., & Levine, D. (2016). Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. *Gynecol Oncol*, 141(2), 260–263.
- Fauzan, R. (2009). Gambaran faktor penggunaan kontrasepsi terhadap angka kejadian kanker ovarium di RSUPN Dr.Cipto Mangunkusumo Jakarta berdasarkan pemeriksaan histopatologik tahun 2003- 2007. *Fakultas Kedokteran Universitas Indonesia*, 4–16.
- Feng, Z., Wen, H., Bi, R., Ju, X., Chen, X., Yang, W., & Wu, X. (2016). Preoperative neutrophil-to-lymphocyte ratio as a predictive and prognostic factor for high-grade serous ovarian cancer. *PLoS ONE*, 11(5), 1–9.
- Gockley, A., Melamed, A., Bregar, A. J., Clemmer, J. T., Birrer, M., Schorge, J. O., Del Carmen, M. G., & Alejandro Rauh-Hain, J. (2017). Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. *Obstetrics and Gynecology*, 129(3), 439–447.
- Hess, L. M., Brnabic, A., Mason, O., Lee, P., & Barker, S. (2019). Relationship between progression-free survival and overall survival in randomized clinical trials of targeted and biologic agents in oncology. *Journal of Cancer*, 10(16), 3717–3727.
- Hoffman, B. et al. (2016). *Williams Gynecology 3rd Edition: Chapter 35 Epithelial Ovarian Cancer* (3rd ed.). McGraw Hill Education.
- Huang, Q. T., Zhou, L., Zeng, W. J., Ma, Q. Q., Wang, W., Zhong, M., & Yu, Y. H. (2017). Prognostic significance of neutrophil-to-lymphocyte ratio in ovarian cancer: A systematic review and meta-analysis of observational studies. *Cellular Physiology and Biochemistry*, 41(6), 2411–2418.

- IARC. (2020). Indonesia - Global Cancer Observatory. *Globocan*, 858, 1–2.
- Javadi, S., Ganeshan, D. M., Qayyum, A., Iyer, R. B., & Bhosale, P. (2016). Ovarian cancer, the revised FIGO staging system, and the role of imaging. *American Journal of Roentgenology*, 206(6), 1351–1360.
- Kim, H. S., Choi, H. Y., Lee, M., Suh, D. H., Kim, K., No, J. H., Chung, H. H., Kim, Y. B., & Song, Y. S. (2016). Systemic inflammatory response markers and CA-125 levels in ovarian clear cell carcinoma: A two center cohort study. *Cancer Research and Treatment*, 48(1), 250–258.
- Klar, M., Hasenburg, A., Hasanov, M., Hilpert, F., Meier, W., Pfisterer, J., Pujade-Lauraine, E., Herrstedt, J., Reuss, A., & du Bois, A. (2016). Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO. *European Journal of Cancer*, 66, 114–124. <http://dx.doi.org/10.1016/j.ejca.2016.07.014>
- Lee, M., Chang, M. Y., Yoo, H., Lee, K. E., Chay, D. B., Cho, H., Kim, S., Kim, Y. T., & Kim, J. H. (2016). Clinical significance of CA125 level after the first cycle of chemotherapy on survival of patients with advanced ovarian cancer. *Yonsei Medical Journal*, 57(3), 580–587.
- Matulonis, U. A., Oza, A. M., Ho, T. W., & Ledermann, J. A. (2015). Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials. *Cancer*, 121(11), 1737–1746.
- McGuire, W., Hoskins, W., Brady, M., Kucera, P., Partidge, E., Look, K., Clarke-Pearson, D., & Davidson, M. (2013). *Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer*. 334(1), 1–6.
- Miao, Y., Yan, Q., Li, S., Li, B., & Feng, Y. (2016). *Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy*. 17, 33–40.

- Nagle, C. M., Dixon, S. C., Jensen, A., Kjaer, S. K., Modugno, F., DeFazio, A., Fereday, S., Hung, J., Johnatty, S. E., Fasching, P. A., Beckmann, M. W., Lambrechts, D., Vergote, I., Van Nieuwenhuysen, E., Lambrechts, S., Risch, H. A., Rossing, M. A., Doherty, J. A., Wicklund, K. G., ... Webb, P. M. (2015). Obesity and survival among women with ovarian cancer: Results from the Ovarian Cancer Association Consortium. *British Journal of Cancer*, *113*(5), 817–826.
- Nezhad, A. K., Ebrahimi, V., Ahmadpour, F., Momtahan, M., Robati, M., Saraf, Z., Ramzi, M., Jowkar, Z., & Ghaffari, P. (2020). Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer. *Cancer Management and Research*, *12*, 1447–1456.
- Nicolás-Ávila, J. Á., Adrover, J. M., & Hidalgo, A. (2017). Neutrophils in Homeostasis, Immunity, and Cancer. *Immunity*, *46*(1), 15–28.
- Nomelini, R., Chiovato, A., Abdulmassih, F., Da Silva, R., Tavares-Murta, B., & Murta, E. (2018). Neutrophil - to - lymphocyte ratio and platelet count as prognostic factors in ovarian malignancies. *Journal of Cancer Research and Therapeutics*, *15*(6), 1226–1230.
- Oza, A. M., Castonguay, V., Tsoref, D., Diaz-Padilla, I., Karakasis, K., Mackay, H., Welch, S., Weberpals, J., Hoskins, P., Plante, M., Provencher, D., Tonkin, K., Covens, A., Ghatage, P., Gregoire, J., Hirte, H., Miller, D., Rosen, B., Bentley, J., ... Stuart, G. C. E. (2011). Corrigendum: Progression-free survival in advanced ovarian cancer: A canadian review and expert panel perspective. *Current Oncology*, *18*(6), 303.
- Paoletti, X., Lewsley, L. A., Daniele, G., Cook, A., Yanaihara, N., Tinker, A., Kristensen, G., Ottevanger, P. B., Aravantinos, G., Miller, A., Boere, I. A., Fruscio, R., Reyners, A. K. L., Pujade-Lauraine, E., Harkin, A., Pignata, S., Kagimura, T., Welch, S., Paul, J., ... Glasspool, R. M. (2020). Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-

analysis. *JAMA Network Open*, 3(1), e1918939.

RKBR. (2018). *Registrasi Kanker Berbasis Rumah Sakit Dr Sardjito/FKKMK UGM*. <http://canreg.fk.ugm.ac.id/laporan-data/rkbr-oktober-2018/>

Santoiemma, P. P., & Powell, D. J. (2015). Tumor infiltrating lymphocytes in ovarian cancer. *Cancer Biology and Therapy*, 16(6), 807–820.

Sjoquist, K., Lord, S., Friedlander, M., Simes, R., Marschner, I., & Lee, C. (2018). Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. *Therapeutic Advances in Medical Oncology*, 10, 1–16.

Sumanasekera, W. K. (2018). Epidemiology of Ovarian Cancer: Risk Factors and Prevention. *Biomedical Journal of Scientific & Technical Research*, 11(2), 1–13.

Wang, Y., Liu, P., Xu, Y., Zhang, W., Tong, L., Guo, Z., & Ni, H. (2015). Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer. *Cancer Chemotherapy and Pharmacology*, 75(2), 255–262.

Webb, P. M., Leader, G., Jordan, S. J., Head, T., & Causes, C. (2016). Best Practice & Research Clinical Obstetrics and Gynaecology Epidemiology of epithelial ovarian cancer. *Best Practice & Research Clinical Obstetrics & Gynaecology*, 1–12.

Wei, W., Li, N., Sun, Y., Li, B., Xu, L., & Wu, L. (2017). Clinical outcome and prognostic factors of patients with earlystage epithelial ovarian cancer. *Oncotarget*, 8(14), 23862–23870.

Williams, K. A., Labidi-Galy, S. I., Terry, K. L., Vitonis, A. F., Welch, W. R., Goodman, A., & Cramer, D. W. (2014). Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. *Gynecologic Oncology*, 132(3), 542–550.

- Xiang, J., Zhou, L., Li, X., Bao, W., Chen, T., Xi, X., He, Y., & Wan, X. (2017). Preoperative monocyte-to-lymphocyte ratio in peripheral blood predicts stages, metastasis, and histological grades in patients with ovarian cancer. *Translational Oncology*, 10(1), 33–39.
- Yildirim, et al. (2015). Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios. *Molecular and Clinical Oncology*, 3(2), 317–321.
- Zhang, W., Liu, K., Hu, G., & Liang, W. (2015). Preoperative platelet / lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients. *Tumor Biol.*
- Zhou, Q., Hong, L., Zuo, M.-Z., & He, Z. (2017). Prognostic significance of neutrophil to lymphocyte ratio in ovarian cancer: evidence from 4,910 patients. *Oncotarget*, 8(40), 68938–68949.
- Zahorec R. (2001) 'Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill', *Bratisl Lek Listy*, 102(1), pp. 5-14.